ESCONDIDO, Calif.--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). MRM-3379 is an orally available, highly brain-penetrant, selective phosphodiestera. ...

TOKYO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or the “Company”), announces that the cumulative number of Proof of Human authentications using the World ID authentication device ‘Orb’ at stores centered on the relaxation salon “Re.Ra.Ku,” operated by its subsidiary MEDIROM Wellness Co., surpassed 20,000 as of December 28, 2025. The Company participates in World (a Proof of Human authentication protocol), ...

Core Viewpoint - MEDIROM Healthcare Technologies Inc. is collaborating with Tools for Humanity and World Foundation to implement Proof of Human technologies, such as World ID, across Japan, aiming to enhance trust in digital interactions and create new revenue streams [2][3][4]. Group 1: Collaboration and Agreements - MEDIROM has signed a Master Service Agreement (MSA) with Tools for Humanity and World Foundation to manage Proof of Human verification locations in Japan, which is expected to generate revenue through operational fees and related services [3]. - A dedicated task force, the "MEDIROM World Proof of Human Task Force," will be established to facilitate the nationwide rollout of Proof of Human technology [3][5]. Group 2: Background and Purpose - The collaboration addresses the challenge of distinguishing between humans and AI online, leveraging blockchain technology to provide a secure method for individuals to prove their humanity without disclosing their identity [4]. - The initiative aims to foster a digital society where everyone can participate confidently, enhancing the social implementation of Proof of Human [5]. Group 3: Key Initiatives - MEDIROM will deploy advanced cameras, known as Orbs, in approximately 300 Re.Ra.Ku Group locations to verify humanness while preserving privacy [6]. - Plans include establishing flagship locations and pop-up stores to enhance accessibility to Proof of Human verification services [11]. Group 4: Leadership Comments - Koji Eguchi, President and CEO of MEDIROM, expressed enthusiasm for the collaboration, emphasizing the importance of establishing a social infrastructure for proving humanness in the age of generative AI [7]. - Tomoe Makino, General Manager of Tools for Humanity Japan, highlighted Japan's leadership in adopting technology and the potential of Proof of Human as essential digital infrastructure [12].

Core Viewpoint - MEDIROM Healthcare Technologies Inc. is collaborating with Tools for Humanity and World Foundation to implement Proof of Human technologies, such as World ID, across Japan, aiming to enhance trust in digital interactions and create new revenue streams [2][3][4]. Group 1: Collaboration and Agreements - MEDIROM has signed a Master Service Agreement (MSA) with Tools for Humanity and World Foundation to manage Proof of Human verification locations in Japan, which is expected to generate revenue through operational fees and related services [3]. - A dedicated task force, the "MEDIROM World Proof of Human Task Force," will be established to facilitate the nationwide rollout of Proof of Human technology [3][5]. Group 2: Background and Purpose - The collaboration addresses the challenge of distinguishing between humans and AI online, leveraging blockchain technology to provide a secure method for individuals to prove their humanity without disclosing their identity [4]. - The initiative aims to foster a digital society where individuals can confidently participate, enhancing trust in online interactions [5][12]. Group 3: Key Initiatives - MEDIROM will deploy advanced cameras, known as Orbs, in approximately 300 Re.Ra.Ku Group locations to verify humanness while preserving privacy [6]. - Plans include establishing flagship locations and pop-up stores to offer Proof of Human verification services in various commercial and public spaces [11]. Group 4: Leadership Comments - Koji Eguchi, President and CEO of MEDIROM, expressed enthusiasm for the collaboration, emphasizing the importance of establishing a social infrastructure for proving humanness in the age of generative AI [7]. - Tomoe Makino, General Manager of Tools for Humanity Japan, highlighted Japan's leadership in adopting technology and the potential of Proof of Human as essential digital infrastructure [12].

Core Viewpoint - MEDIROM Healthcare Technologies Inc. is collaborating with Tools for Humanity and World Foundation to implement Proof of Human technologies, including World ID, across Japan, aiming to enhance trust in digital interactions and create new revenue streams for the company [2][3][4]. Group 1: Collaboration Details - MEDIROM has signed a Master Service Agreement with Tools for Humanity and World Foundation to manage Proof of Human verification locations in Japan, leveraging its network of approximately 300 physical locations [3][5]. - A dedicated task force, the "MEDIROM World Proof of Human Task Force," will be established to facilitate the nationwide rollout of this technology [3][5]. Group 2: Background and Purpose - The collaboration addresses the challenge of distinguishing between humans and AI online, which has become increasingly difficult due to advancements in generative AI [4]. - The World project aims to provide a blockchain-based mechanism for individuals to prove their humanity without revealing their identity, thereby fostering trust in digital environments [4][5]. Group 3: Key Initiatives - MEDIROM plans to expand its reach by establishing flagship locations and pop-up stores for Proof of Human verification services, enhancing accessibility for users [7][9]. - The company will utilize advanced camera technology, known as Orbs, to verify humanness at approximately 300 Re.Ra.Ku Group locations [9]. Group 4: Leadership Comments - Koji Eguchi, President and CEO of MEDIROM, expressed excitement about the collaboration, emphasizing the importance of establishing a social infrastructure for proving one's humanity in the digital age [6]. - Tomoe Makino, General Manager of Tools for Humanity Japan, highlighted Japan's leadership in adopting technology and the potential of Proof of Human as essential digital infrastructure [11].

Core Insights - MEDIROM Healthcare Technologies Inc. has announced a distributor agreement with TD SYNNEX K.K. to enhance the distribution of its health-tech products, specifically the MOTHER Bracelet and REMONY system [2][3][4] Company Overview - MEDIROM MOTHER Labs Inc. is a subsidiary of MEDIROM Healthcare Technologies, focusing on health-tech solutions, including the development and sales of the MOTHER Bracelet and the REMONY health monitoring system [13] - The MOTHER Bracelet is a unique 24/7 recharge-free smart tracker that measures key health metrics such as heart rate, calories burned, body temperature, step count, and sleep without needing to be removed for charging [7][10] Partnership Initiatives - The collaboration with TD SYNNEX aims to leverage its extensive sales network and expertise in IT product distribution to accelerate the nationwide expansion of MEDIROM's health management solutions [3][4] - TD SYNNEX has a proven track record in the Japanese market for successfully distributing smart trackers, which will benefit the partnership [4] Product Features - The MOTHER Bracelet utilizes advanced technology to generate electricity from temperature differences, ensuring continuous operation without recharging [7] - The REMONY system integrates the MOTHER Bracelet with a dedicated gateway for real-time health monitoring and data synchronization, addressing common issues of data loss during device charging [10][12] - The system is customizable for various industries, including elder care and health monitoring for night shift workers, enhancing its applicability [12]

Core Insights - Mirum Pharmaceuticals has initiated the BLOOM Phase 2 clinical study for MRM-3379 targeting Fragile X syndrome (FXS) [1] - FXS is the most common inherited form of intellectual disability and autism spectrum disorder, affecting approximately 50,000 males in the U.S. and E.U. [1] - Currently, there are no approved therapies for Fragile X syndrome [1]

Core Viewpoint - MEDIROM MOTHER Labs has completed a private placement of new shares valued at ¥9 billion as part of its Series A funding round, involving key management members as investors to enhance business responsibility and growth motivation [1][2]. Group 1: Company Overview - MEDIROM MOTHER Labs is a subsidiary of MEDIROM Healthcare Technologies Inc., focusing on health tech, specifically through the "Lav" healthcare app and the "MOTHER Bracelet" wearable device [5]. - The company aims to provide customizable health management solutions across various sectors, including caregiving, logistics, and manufacturing [5]. Group 2: Business Strategy - The completion of the capital increase will strengthen MEDIROM MOTHER Labs' capital base, enabling accelerated development of upgraded versions of the "MOTHER Bracelet" and the establishment of systems for launching new products [3]. - The management team becoming investors is intended to enhance swift decision-making and a field-driven management structure, thereby increasing business responsibility [2]. Group 3: Future Outlook - MEDIROM MOTHER Labs plans to deliver new value in the healthcare and wellness field, driving sustainable growth both domestically and internationally [3].

Core Insights - The company has launched a new treasury strategy that involves holding Worldcoin (WLD) as a reserve asset to diversify business activities and mitigate financial risks [1][10] - The company aims to incentivize large-scale vital data collection through the distribution of WLD to users of its MOTHER Bracelet, targeting specific medical conditions [2][10] - The board has approved this strategy and will conduct risk analysis at each meeting before implementation [3] Treasury Strategy Objectives - The strategy focuses on exploring new business growth opportunities by leveraging digital assets [10] - It aims to utilize WLD as an incentive for collecting vital data from a larger patient population [10] - The company plans to hedge risks through diversification of its held assets, including holding Ethereum (ETH) as a secondary asset [10] Asset Management and Transparency - The company will promote asset management utilizing crypto assets while ensuring transparency in its treasury strategy [4] - Information regarding the status of held assets, investment policies, and risks will be disclosed in a timely manner [4]

Core Insights - MEDIROM Healthcare Technologies Inc. has surpassed 10,000 verifications of World ID at its wellness salons in Japan, indicating strong adoption of the proof of human technology [1][2] - The company plans to expand the installation of the Orb, an advanced camera for verifying humanness, to 200 stores, enhancing its service capabilities [1] - The increase in World ID verifications is expected to improve the convenience and reliability of digital social infrastructure, contributing to revenue growth for MEDIROM [2] Company Overview - MEDIROM operates over 300 wellness salons under the "Re.Ra.Ku" brand across Japan, providing various health and wellness services [8][11] - The company has expanded into HealthTech since 2015, offering on-demand training apps and manufacturing health monitoring devices like the MOTHER Bracelet [11] Technology and Services - World ID is a global authentication technology that proves "humanness" rather than identity, addressing challenges posed by the rise of generative AI [3] - The Orb camera is utilized to verify individuals' humanness without revealing their identities, supporting the World ID initiative [3][4]